Contents
What is Relapsing-Remitting Multiple Sclerosis? Understanding the Most Common Form of MS
Published: Sep 27, 2023
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of MS, affecting about 85% of patients initially. But what exactly is RRMS and how does it impact those living with it?
Defining RRMS
RRMS is characterized by clearly defined attacks of new or worsening neurologic symptoms, called relapses or exacerbations. These relapses are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods between disease relapses.
Symptoms and Impact
Symptoms of RRMS can vary widely but often include fatigue, numbness, vision problems, muscle spasms or weakness, and difficulty with balance and coordination. The unpredictable nature of relapses can make it challenging for people with RRMS to plan their lives. However, many people with RRMS are able to maintain their normal activities with proper treatment and management strategies.
Diagnosis and Monitoring
Diagnosing RRMS involves a combination of clinical evaluation, MRI scans, and sometimes other tests like spinal fluid analysis. Once diagnosed, regular monitoring through clinical check-ups and MRI scans is crucial. This helps track disease activity and guide treatment decisions. The goal is to catch and treat relapses early, and to prevent new lesions from forming in the brain and spinal cord.
Frequently Asked Questions
It's the initial diagnosis for about 85% of MS patients.
There's no cure, but treatments can reduce relapses and slow progression.
Sometimes, but some symptoms may persist.
Living with RRMS
While RRMS presents challenges, many people lead full, active lives with proper treatment and management.
References
- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018; 90:777.
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24:96.
- Freedman MS, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci 2020; 47:437.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.
AI Doctor Visit Required
Appointments available 24/7
Top licensed doctors
Available in all 50 states
Full service care
Prescriptions, referrals & treatment
No insurance needed
All notes available in Doctronic
15-min consultation. No hidden costs.
AI Doctor Visit Required
Please Chat With Our AI Doctor First
Our AI doctor assessment helps our human doctors prepare for your video visit and provide better care
For safety reasons we have been forced to end this consultation.
If you believe this is a medical emergency please call 911 or your local emergency services immediately.
If you are experiencing emotional distress, please call the the Suicide & Crisis Lifeline at 988 or your local crisis services immediately.
Contact us
You can also email us at help@doctronic.ai
We aim to reply within 5-7 days
How likely are you to recommend Doctronic to friends or family?